Sangamo Therapeutics, Inc. (SGMO) Dividend History

Sangamo Therapeutics, Inc. (SGMO) is a biotechnology company specializing in gene editing and gene therapy technologies. Founded in 1995, the company focuses on developing genomic medicines to treat and potentially cure genetic diseases, hemophilia, and cell and gene therapy applications. Sangamo utilizes its proprietary zinc finger nuclease (ZFN) platform to engineer precise genomic modifications, aiming to advance innovative treatments across multiple therapeutic areas.

501 Canal Blvd., Richmond, CA, 94084
Phone: (510) 970-6000
Website: https://www.sangamo.com

Dividend History

Sangamo Therapeutics, Inc. currently does not pay dividends

Company News

US Futures Show Caution Among Investors Ahead Of FOMC Meeting: Analysts Say Only Certainty Is That 'Things Will Remain Uncertain For The Time Being'

U.S. stock futures were flat on Tuesday as investors remained cautious ahead of the FOMC meeting. Analysts say the only certainty is that 'things will remain uncertain for the time being'.

Benzinga

Featured Companies: BKKT BON GES GETY HQY HROW HROWL HROWM IHS QQQ SPY STN
Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight

The cell and gene therapies in rare disorders market is expected to grow significantly by 2034, driven by an increase in approvals and adoption of these treatments, ability to treat a broad array of conditions, and rising prevalence of rare disorders.

GlobeNewswire Inc.

Featured Companies: ABEO BCLI CAPR EDIT FDMT FOLD OCGN PFE RARE RGNX
Global Mucopolysaccharidosis Treatment Market to Witness Robust Growth, Projected to Reach USD 5,014.5 Million by 2035 Growing at a CAGR of 5.9% | FMI

The global mucopolysaccharidosis treatment market is expected to grow significantly, driven by advancements in biotechnology, improved diagnostic techniques, and increased awareness of rare diseases. The market is projected to reach $5,014.5 million by 2035, growing at a CAGR of 5.9%.

GlobeNewswire Inc.

Featured Companies: ABEO BMRN RARE RGNX SRPT
Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact

Sangamo Therapeutics regained rights to its hemophilia gene therapy after Pfizer terminated their collaboration. The Phase 3 trial met its objectives, but Sangamo was surprised and disappointed by Pfizer's decision to end the partnership.

Benzinga

Featured Companies: PFE
mRNA Therapeutics Market Size to Hit USD 48.65 Billion by 2032 due to Advances in Cancer Treatment and Expanding mRNA Vaccine Applications | Research by SNS Insider

The mRNA therapeutics market is expected to grow significantly, driven by the success of mRNA-based COVID-19 vaccines and the expanding applications of mRNA technology in areas like cancer treatment and infectious diseases.

GlobeNewswire Inc.

Featured Companies: ARCT CRSP CVAC MRNA PFE

Dividend data last updated 06/07/2025 02:01:44 UTC